Advertisement

Influential Factors on Risk-reduction Mastectomy in a High-risk Breast Cancer Population With Genetic Predispositions

  • Grace Wei
    Affiliations
    MD Program, University of South Florida Morsani College of Medicine, Tampa, FL
    Search for articles by this author
  • Ambuj Kumar
    Affiliations
    Center for Evidence-based Medicine and Health Outcomes Research, University of South Florida, Tampa, FL
    Search for articles by this author
  • Marie Catherine Lee
    Affiliations
    Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
    Search for articles by this author
  • Xia Wang
    Correspondence
    Address for correspondence: Xia Wang, MD PhD, FACMG, GeneHome Hereditary Cancer Screening Clinic, NFCN Multidisciplinary Neurofibromatosis Clinic, TS Alliance Multidisciplinary Tuberous Sclerosis Clinic, H. Lee Moffitt Cancer Center and Research Institute, 10920 N. McKinley Dr, Tampa, FL 33612
    Affiliations
    GeneHome Hereditary Cancer Screening Clinic, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
    Search for articles by this author
Published:January 19, 2021DOI:https://doi.org/10.1016/j.clbc.2021.01.008

      Abstract

      Background

      Carriers of deleterious mutations in breast cancer predisposition genes are presented with critical choices regarding cancer risk management. Risk-reduction mastectomy is a major preventative strategy in this population. Understanding the decision-making process for prophylactic mastectomy is essential in patient-centered care for high-risk carriers and patients with breast cancer. We sought to provide insight into influential factors underlying preventative surgery decisions among individuals with high breast cancer risk.

      Materials and Methods

      We conducted a retrospective chart review of pathogenic carriers of high-risk breast cancer genes who presented to the Moffitt GeneHome clinic between March 2017 and June 2020. Associations between preventative mastectomy choice and influence variables were analyzed via unadjusted and adjusted logistic regression models.

      Results

      Of 258 high-risk mutation carriers, 104 (40.3%) underwent risk-reduction mastectomy. A significantly higher proportion of mastectomy patients reported prior history of breast cancer (68.9% vs. 16.5%; P < .001) and history of other risk-reduction or noncancer-related surgeries (61.7% vs. 25.8%; P < .001). Significant predictors affecting surgery decision included previous breast cancer history (adjusted odds ratio [aOR], 10.48; 95% confidence interval [CI], 5.59-19.63; P < .0001), other risk-reduction or noncancer-related surgical history (aOR, 4.65; 95% CI, 2.28-9.47; P < .0001), and age at presentation to the genetics clinic (< 35 years old: aOR, 2.77; 95% CI, 1.04-7.4; P = .042; 35-55 years old: aOR, 2.48; 95% CI, 1.19-5.18; P = .016).

      Conclusions

      Preventive mastectomy decisions are highly personal and complex. In our sample, we observed prior history or concurrent breast cancer, history of other risk-reduction surgery or noncancer-related surgery, and younger age at presentation to the GeneHome clinic to be predictive of mastectomy uptake.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hartmann L.C.
        • Schaid D.J.
        • Woods J.E.
        • et al.
        Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.
        N Engl J Med. 1999; 340: 77-84
        • Heemskerk-Gerritsen B.A.M.
        • Menke-Pluijmers M.B.E.
        • Jager A.
        • et al.
        Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis.
        Ann Oncol. 2013; 24: 2029-2035
        • Arrington A.K.
        • Jarosek S.L.
        • Virnig B.A.
        • Habermann E.B.
        • Tuttle T.M.
        Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer.
        Ann Surg Oncol. 2009; 16: 2697-2704
        • Soran A.
        • Kamali Polat A.
        • Johnson R.
        • McGuire K.P.
        Increasing trend of contralateral prophylactic mastectomy: what are the factors behind this phenomenon?.
        Surgeon. 2014; 12: 316-322
        • Johns D.
        • Agarwal J.
        • Anderson L.
        • Ying J.
        • Kohlmann W.
        Breast cancer risk reduction decisions of the BRCA-positive patient: an observational study at a single institution.
        J Womens Health (Larchmont). 2017; 26: 702-706
        • Kuchenbaecker K.B.
        • Hopper J.L.
        • Barnes D.R.
        • et al.
        • BRCA1 and BRCA2 Cohort Consortium
        Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
        JAMA. 2017; 317: 2402-2416
        • Carbine N.E.
        • Lostumbo L.
        • Wallace J.
        • Ko H.
        Risk-reducing mastectomy for the prevention of primary breast cancer.
        Cochrane Database Syst Rev. 2018; 4: CD002748
        • Antoniou A.C.
        • Foulkes W.D.
        • Tischkowitz M.
        Breast-cancer risk in families with mutations in PALB2.
        N Engl J Med. 2014; 371: 1651-1652
        • Hansford S.
        • Kaurah P.
        • Li-Chang H.
        • et al.
        Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond.
        JAMA Oncol. 2015; 1: 23-32
        • Mai P.L.
        • Best A.F.
        • Peters J.A.
        • et al.
        Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
        Cancer. 2016; 122: 3673-3681
        • Tan M.H.
        • Mester J.L.
        • Ngeow J.
        • Rybicki L.A.
        • Orloff M.S.
        • Eng C.
        Lifetime cancer risks in individuals with germline PTEN mutations.
        Clin Cancer Res. 2012; 18: 400-407
        • Antoniou A.C.
        • Casadei S.
        • Heikkinen T.
        • et al.
        Breast-cancer risk in families with mutations in PALB2.
        N Engl J Med. 2014; 371: 497-506
        • Gumus M.
        • Ustaalioglu B.O.
        • Garip M.
        • et al.
        Factors that affect patients’ decision-making about mastectomy or breast conserving surgery, and the psychological effect of this choice on breast cancer patients.
        Breast Care (Basel). 2010; 5: 164-168
        • Manoukian S.
        • Alfieri S.
        • Bianchi E.
        • Peissel B.
        • Azzollini J.
        • Borreani C.
        Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: are there factors associated with the choice?.
        Psychooncology. 2019; 28: 1871-1878
        • Welsh J.L.
        • Hoskin T.L.
        • Day C.N.
        • et al.
        Clinical decision-making in patients with variant of uncertain significance in BRCA1 or BRCA2 genes.
        Ann Surg Oncol. 2017; 24: 3067-3072
        • Covelli A.M.
        • Baxter N.N.
        • Fitch M.I.
        • McCready D.R.
        • Wright F.C.
        ‘Taking control of cancer’: understanding women’s choice for mastectomy.
        Ann Surg Oncol. 2015; 22: 383-391
        • Gu J.
        • Groot G.
        • Boden C.
        • Busch A.
        • Holtslander L.
        • Lim H.
        Review of factors influencing women’s choice of mastectomy versus breast conserving therapy in early stage breast cancer: a systematic review.
        Clin Breast Cancer. 2018; 18: e539-e554
        • Howard A.F.
        • Balneaves L.G.
        • Bottorff J.L.
        Women’s decision making about risk-reducing strategies in the context of hereditary breast and ovarian cancer: a systematic review.
        J Genet Couns. 2009; 18: 578-597
        • Meiser B.
        • Quinn V.F.
        • Mitchell G.
        • et al.
        • TFGT Collaborative Group
        Psychological outcomes and surgical decisions after genetic testing in women newly diagnosed with breast cancer with and without a family history.
        Eur J Hum Genet. 2018; 26: 972-983
        • Singh K.
        • Lester J.
        • Karlan B.
        • Bresee C.
        • Geva T.
        • Gordon O.
        Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
        Am J Obstet Gynecol. 2013; 208: 329.e1-329.e6
        • Yi M.
        • Hunt K.K.
        • Arun B.K.
        • et al.
        Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy.
        Cancer Prev Res (Phila). 2010; 3: 1026-1034
      1. Hereditary Breast and Ovarian Cancer: BRCA1 and BRCA2. Centers for Disease Control and Prevention, 2020.
        (Available at:)
        • Litton J.K.
        • Westin S.N.
        • Ready K.
        • et al.
        Perception of screening and risk-reduction surgeries in patients tested for a BRCA deleterious mutation.
        Cancer. 2009; 115: 1598-1604
        • Fu Y.
        • Zhuang Z.
        • Dewing M.
        • Apple S.
        • Chang H.
        Predictors for contralateral prophylactic mastectomy in breast cancer patients.
        Int J Clin Exp Pathol. 2015; 8: 3748-3764
        • Glassey R.
        • O’Connor M.
        • Ives A.
        • Saunders C.
        • O’Sullivan S.
        • Hardcastle S.J.
        • kConFab Investigators
        Heightened perception of breast cancer risk in young women at risk of familial breast cancer.
        Fam Cancer. 2018; 17: 15-22
        • Verhoog L.C.
        • Brekelmans C.T.
        • Seynaeve C.
        • Meijers-Heijboer E.J.
        • Klijn J.G.
        Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer.
        Br J Cancer. 2000; 83: 384-386
        • Teoh V.
        • Tasoulis M.-K.
        • Gui G.
        Contralateral prophylactic mastectomy in women with unilateral breast cancer who are genetic carriers, have a strong family history or are just young at presentation.
        Cancers (Basel). 2020; 12: 140
        • Henry D.A.
        • Lee M.C.
        • Almanza D.
        • et al.
        Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE).
        Breast Cancer Res Treat. 2019; 174: 39-45
        • Metcalfe K.A.
        • Narod S.A.
        Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy.
        J Natl Cancer Inst. 2002; 94: 1564-1569